WO2015098763A1 - 医療用具 - Google Patents
医療用具 Download PDFInfo
- Publication number
- WO2015098763A1 WO2015098763A1 PCT/JP2014/083755 JP2014083755W WO2015098763A1 WO 2015098763 A1 WO2015098763 A1 WO 2015098763A1 JP 2014083755 W JP2014083755 W JP 2014083755W WO 2015098763 A1 WO2015098763 A1 WO 2015098763A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- repeating unit
- copolymer
- carbon atoms
- mol
- group
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/0005—Use of materials characterised by their function or physical properties
- A61L33/0011—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate
- A61L33/0035—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate using a polymer with positively charged atoms in the polymeric backbone, e.g. ionenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/0005—Use of materials characterised by their function or physical properties
- A61L33/0011—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate
- A61L33/0023—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate using a quaternized group or a protonated amine group of the substrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/048—Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/06—Use of macromolecular materials
- A61L33/064—Use of macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/06—Use of macromolecular materials
- A61L33/068—Use of macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/42—Anti-thrombotic agents, anticoagulants, anti-platelet agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
- A61L2300/604—Biodegradation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/606—Coatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2420/00—Materials or methods for coatings medical devices
- A61L2420/02—Methods for coating medical devices
Definitions
- the present invention relates to a medical device. More specifically, the present invention relates to a medical device having excellent antithrombogenicity.
- imparting antithrombogenicity to a medical device is performed by a method of coating a base material constituting the medical device with an antithrombotic material or a method of fixing an antithrombotic material on the surface of the base material.
- Japanese Patent Application Laid-Open No. 4-152955 discloses on the surface a synthetic polymer that simultaneously satisfies biocompatibility such as suppression of platelet adhesion / activation, inhibitory effect of complement system activation, and affinity with tissue in vivo.
- An artificial organ membrane or medical device is disclosed.
- US Patent Application Publication No. 2008/0262181 (corresponding to International Publication No. 2005/113620) is a homopolymer that exhibits excellent biocompatibility with reduced interaction with biological components such as proteins and blood cells.
- a biocompatible material comprising a copolymer is disclosed.
- an object of the present invention is to provide a medical device that is excellent in antithrombogenicity under severe conditions in which thrombus is easily formed.
- the present invention has the following contents.
- a medical device having a base material and a coating layer containing an antithrombotic material that covers the surface of the base material,
- the antithrombotic material is Following formula (1):
- R 11 is a hydrogen atom or a methyl group
- Z is an oxygen atom or —NH—
- R 12 is an alkylene group having 1 to 6 carbon atoms
- R 13 and R 14 are each independently An alkyl group having 1 to 4 carbon atoms
- R 15 is an alkylene group having 1 or 2 carbon atoms
- R 21 is a hydrogen atom or a methyl group
- R 22 is an alkylene group having 1 to 6 carbon atoms
- R 23 is an alkyl group having 1 to 4 carbon atoms.
- R 21 is a hydrogen atom or a methyl group
- R 22 is an alkylene group having 1 to 3 carbon atoms
- R 23 is an alkyl group having 1 or 2 carbon atoms. 1 above. Medical devices as described in; 3.
- R 11 is a methyl group
- Z is an oxygen atom
- R 12 is an alkylene group having 1 to 3 carbon atoms
- R 13 and R 14 are each independently the number of carbon atoms.
- the copolymer comprises 1 to 7 mol% of the repeating unit (A) and 99 to 93 mol% of the repeating unit (B) (the total amount of the repeating unit (A) and the repeating unit (B) is 100%).
- the medical device in any one of.
- FIG. 1 shows a tube (stepped tube) used in the example and having both ends connected by connectors.
- a portion surrounded by a circle indicates a joint portion between the tube 1 and the tube 2.
- FIG. 2 is an enlarged view schematically showing a cross section in the major axis direction at the joint between the tube 1 and the tube 2 in FIG.
- FIG. 3 is an enlarged photograph of the joint immediately after the antithrombogenicity test on the stepped tube to which the antithrombogenic material containing the polymer (1) produced in Example 1 is applied.
- FIG. 4 is an enlarged photograph of the joint immediately after the antithrombogenicity test for the stepped tube to which the antithrombogenic material containing the comparative polymer (3) produced in Comparative Example 3 is applied.
- FIG. 5 is a photograph immediately after the blood circulation test on the blood circulation module to which the antithrombotic material containing the polymer (1) produced in Example 1 is applied.
- FIG. 6 is a photograph immediately after the blood circulation test on the blood circulation module to which the antithrombotic material containing the comparative polymer (5) produced in Comparative Example 5 is applied.
- the present invention relates to a medical device coated with an antithrombogenic material containing a copolymer having a specific repeating unit.
- X to Y indicating a range means “X or more and Y or less”, “weight” and “mass”, “weight%” and “mass%”, “part by weight” and “weight part”. “Part by mass” is treated as a synonym. Unless otherwise specified, measurement of operation and physical properties is performed under conditions of room temperature (20 to 25 ° C.) / Relative humidity 40 to 50%.
- the present invention is a medical device having a base material and a coating layer containing an antithrombotic material that covers the surface of the base material, wherein the antithrombogenic material is: Following formula (1):
- R 11 is a hydrogen atom or a methyl group
- Z is an oxygen atom or —NH—
- R 12 is an alkylene group having 1 to 6 carbon atoms
- R 13 and R 14 are each independently An alkyl group having 1 to 4 carbon atoms
- R 15 is an alkylene group having 1 or 2 carbon atoms
- R 21 is a hydrogen atom or a methyl group
- R 22 is an alkylene group having 1 to 6 carbon atoms
- R 23 is an alkyl group having 1 to 4 carbon atoms.
- the coating layer antithrombogenic material forming the coating layer
- the coating layer which is a characteristic element of the present invention
- the coat layer is a layer that covers at least a part of the surface of the base material, and is provided to impart antithrombogenic properties to the medical device.
- the antithrombogenic material constituting the coating layer includes a repeating unit (A) represented by the above formula (1) (hereinafter also simply referred to as “repeating unit (A)”) and a repeating unit represented by the above formula (2). (B) (hereinafter also simply referred to as “repeating unit (B)”), and the copolymer contains 1 to 7 repeating units (A) in all the structural units. It is characterized by containing mol%.
- the inventors have obtained a medical device having excellent antithrombogenicity by combining the repeating unit (A) with the repeating unit (B) and forming a coat layer using a copolymer containing these repeating units. I found out that
- Japanese Patent Application Laid-Open No. 4-152955 discloses a biocompatible medical material using a homopolymer of the repeating unit (B) or a copolymer containing the same, but as described above, thrombus is very formed.
- the copolymer is carboxybetaine. It has been found that the antithrombogenicity can be improved by including a skeleton containing a zwitterion such as a skeleton as a repeating unit.
- Such an improvement in antithrombogenicity is the effect of inhibiting thrombus formation as a result of the hydrophilicity of the copolymer being moderately controlled and biocompatibility increased by including a highly hydrophilic repeating unit (A). This is thought to be due to a dramatic improvement.
- the antithrombotic material fixed to the medical device is eluted quickly, the antithrombogenicity of the medical device may decrease during the operation, and a large amount of blood clots may be generated in the blood vessel circuit, making it impossible to use the blood circuit. There is.
- the content ratio of the repeating unit (A) in all the constituent units of the copolymer is set to 7 mol% as the upper limit, thereby exhibiting excellent antithrombogenicity and a coat layer in which water solubility is appropriately controlled. Can be formed.
- a medical device that is excellent in antithrombogenicity under severe conditions in which thrombus is easily formed.
- the copolymer contained in the antithrombotic material according to the present invention contains the above repeating units (A) and (B), and the content ratio of the repeating unit (A) is within a specific range among all the structural units. It is a certain copolymer. Therefore, if it has the said composition, the terminal in particular of a copolymer will not be restrict
- the structure of the copolymer is not particularly limited, and may be any of a random copolymer, an alternating copolymer, a periodic copolymer, and a block copolymer.
- the weight average molecular weight of the copolymer is preferably 1,000 to 1,000,000. When included in the above range, it is preferable from the viewpoint of solubility.
- the weight average molecular weight of the copolymer is more preferably 50,000 to 500,000 from the viewpoint of easy coating of the coat layer.
- the value measured by gel permeation chromatography (Gel permeation chromatography) using polystyrene as a standard substance and tetrahydrofuran (THF) as a mobile phase is adopted as the “weight average molecular weight”.
- repeating unit (A) In the present invention, the copolymer contained in the antithrombotic material essentially contains the repeating unit (A) represented by the above formula (1).
- R 11 is a hydrogen atom or a methyl group, and preferably a methyl group from the viewpoint of improving antithrombogenicity.
- Z is an oxygen atom or —NH—, and is preferably an oxygen atom from the viewpoint of improving antithrombogenicity.
- R 12 is a linear or branched alkylene group having 1 to 6 carbon atoms, specifically, a methylene group, an ethylene group, a trimethylene group, a propylene group, a tetramethylene group, A pentamethylene group, a hexamethylene group, etc. are mentioned.
- a linear or branched alkylene group having 1 to 3 carbon atoms is preferable, a methylene group or an ethylene group is more preferable, and an ethylene group is particularly preferable.
- R 13 and R 14 are each independently an alkyl group having 1 to 4 carbon atoms, specifically, methyl group, ethyl group, propyl group, isopropyl group, butyl group, Examples thereof include a linear or branched alkyl group such as an isobutyl group, a sec-butyl group, and a tert-butyl group. Among these, from the viewpoint of improving antithrombogenicity, a linear or branched alkyl group having 1 to 3 carbon atoms is preferable, and an alkyl group having 1 or 2 carbon atoms (methyl group, ethyl group) is preferable. And more preferably a methyl group.
- R 15 is a linear or branched alkylene group having 1 or 2 carbon atoms, and specific examples include a methylene group and an ethylene group. Of these, an alkylene group having 1 carbon atom (methylene group) is particularly preferred from the viewpoint of improving antithrombogenicity.
- R 11 is a methyl group
- Z is an oxygen atom
- R 12 is an alkylene group having 1 to 3 carbon atoms
- R 13 and R 14 is preferably independently an alkyl group having 1 or 2 carbon atoms.
- R 11 is a methyl group
- Z is an oxygen atom
- R 12 is an alkylene group having 2 carbon atoms
- R 13 and R 14 are each independently the number of carbon atoms. Particularly preferred is 1 alkyl group.
- the copolymer contained in the antithrombogenic material in the present invention forms a monomer (hereinafter also referred to as “monomer a”) that forms the repeating unit (A) and a repeating unit (B) that will be described in detail below.
- a monomer hereinafter also referred to as “monomer b”.
- Examples of the monomer a include N- (meth) acryloyloxymethyl-N, N-dimethylammonium- ⁇ -N-methylcarboxybetaine, N- (meth) acryloyloxyethyl-N, N-dimethylammonium- ⁇ -N.
- the said monomer may be used individually by 1 type or in mixture of 2 or more types. By using such a monomer having a betaine skeleton, high antithrombogenicity can be imparted to the coat layer of a medical device.
- “(meth) acryl” means “acryl” and / or “methacryl”
- (meth) acryloyl” means “acryloyl” and / or “methacryloyl”.
- repeating unit (B) In the present invention, the copolymer contained in the antithrombotic material essentially contains the repeating unit (B) represented by the above formula (2).
- R 21 is a hydrogen atom or a methyl group, and is preferably a hydrogen atom from the viewpoint of improving antithrombogenicity.
- R 22 is a linear or branched alkylene group having 1 to 6 carbon atoms, and specifically includes a methylene group, an ethylene group, a trimethylene group, a propylene group, a tetramethylene group, A pentamethylene group, a hexamethylene group, etc. are mentioned.
- a linear or branched alkylene group having 1 to 3 carbon atoms is preferable, a methylene group or an ethylene group is more preferable, and an ethylene group is particularly preferable.
- R 23 is a linear or branched alkyl group having 1 to 4 carbon atoms, specifically, methyl group, ethyl group, propyl group, isopropyl group, butyl group, isobutyl. And a linear or branched alkyl group of a group, a sec-butyl group, and a tert-butyl group.
- a linear or branched alkyl group having 1 to 3 carbon atoms is preferable, and an alkyl group having 1 or 2 carbon atoms (methyl group, ethyl group) is preferable. And more preferably a methyl group.
- R 21 is a hydrogen atom or a methyl group
- R 22 is an alkylene group having 1 to 3 carbon atoms
- R 23 is a carbon atom.
- An alkyl group having 1 or 2 atoms is preferable.
- R 21 is a hydrogen atom or a methyl group
- R 22 is an alkylene group having 2 carbon atoms
- R 23 is an alkyl group having 1 carbon atom. preferable.
- Monomer b is preferably methoxymethyl acrylate, methoxyethyl acrylate (MEA), ethoxymethyl acrylate, ethoxyethyl acrylate, methoxymethyl methacrylate, methoxyethyl methacrylate, ethoxymethyl methacrylate, ethoxyethyl methacrylate.
- MEA methoxyethyl acrylate
- the said monomer may be used individually by 1 type or in mixture of 2 or more types.
- the copolymer contains 1 to 7 mol% of the repeating unit (A) in all the structural units (100 mol%) of the copolymer. Since the repeating unit (A) has high hydrophilicity, when the copolymer is contained in a large amount in the copolymer, the copolymer exhibits good antithrombogenicity. On the other hand, when there are too many repeating units (A), the water solubility of a copolymer will become high, and when an antithrombotic material is applied to a medical device, there exists a possibility that an antithrombogenic material may peel.
- the repeating unit (A) When the repeating unit (A) is present in a proportion of less than 1 mol% in all the structural units of the copolymer, a sufficient antithrombotic improvement effect cannot be obtained, and the copolymer is used for a long time under conditions where thrombus is easily formed. A thrombus is formed in such a harsh environment.
- the repeating unit (A) exceeds 7 mol%, the antithrombotic property coated on the medical device when it comes into contact with a body fluid (for example, blood) due to the water-solubility-imparting action of the repeating unit (A). There is a risk that the material peels off from the base material and is eluted (mixed) into the body fluid.
- (A) is preferably 2 to 6 mol% in all the structural units, and preferably 3 to 5 mol%. More preferably.
- the content ratio of the repeating unit (B) is not particularly limited as long as the repeating unit (A) is within the above range in all the structural units, but the entire structure of the copolymer is not limited.
- the repeating unit (B) is preferably contained in an amount of 60 mol% or more, more preferably 80 mol% or more, and particularly preferably 90 mol% or more.
- the upper limit is 99 mol% from the relationship with the repeating unit (A).
- the copolymer contained in the antithrombotic material may contain constituent units other than the repeating units (A) and (B), but is composed of only the repeating units (A) and (B). And preferred. That is, in the copolymer contained in the antithrombogenic material, the total amount of the repeating unit (A) and the repeating unit (B) is preferably 100 mol%.
- the copolymer contains 1 to 7 mol% of the repeating unit (A) and 99 to 93 mol% of the repeating unit (B) (the total amount of the repeating unit (A) and the repeating unit (B) is 100%. It is preferably composed of (mol%).
- the copolymer contained in the antithrombotic material contains 2 to 6 mol% of the repeating unit (A) and 98 to 94 mol% of the repeating unit (B) (the repeating unit (A) and the repeating unit (B) The total amount of) is more preferably 100 mol%. Furthermore, the copolymer has a repeating unit (A) of 3 to 5 mol% and a repeating unit (B) of 97 to 95 mol% (the total amount of the repeating unit (A) and the repeating unit (B) is 100 mol%) is particularly preferable.
- the value determined by the NMR method is adopted as the ratio of the repeating unit (A), the repeating unit (B), or the repeating unit derived from another monomer in the copolymer.
- each of the repeating units (A) and (B) has a characteristic structure of an alkylene group on the nitrogen atom ( That is, the integrated value of 1 H-NMR of R 15 ) and the alkoxy group (that is, —OR 23 ) was determined, and based on the ratio of the integrated value, the repeating unit (A) and repeating unit ( B) can be analyzed. Further, in the measurement of 1 H-NMR, when the peaks overlap, it can be calculated using 13 C-NMR.
- the copolymer contained in the antithrombotic material according to the present invention is preferably composed of only the repeating units (A) and (B), but includes other repeating units. May be. That is, in another embodiment of the present invention, the copolymer contained in the antithrombotic material includes monomer a, monomer b, and another monomer copolymerizable therewith (hereinafter simply referred to as “other monomer”).
- the structural unit (repeating unit) derived from the above may be included.
- Examples of other monomers copolymerizable with monomer a and monomer b include acrylamide, N, N-dimethylacrylamide, N, N-diethylacrylamide, aminomethyl acrylate, aminoethyl acrylate, aminoisopropyl acrylate, diaminomethyl acrylate, Diaminoethyl acrylate, diaminobutyl acrylate, methacrylamide, N, N-dimethylmethacrylamide, N, N-diethylmethacrylamide, aminomethyl methacrylate, aminoethyl methacrylate, diaminomethyl methacrylate, diaminoethyl methacrylate, methyl acrylate, ethyl acrylate, isopropyl Acrylate, butyl acrylate, 2-ethylhexyl acrylate, methyl methacrylate, Methacrylate, butyl methacrylate, hexyl acrylate, hexyl methacryl
- the ratio of the repeating unit derived from the other monomer is not particularly limited in the total constitutional unit of the copolymer, but is, for example, more than 0 mol% and less than 39 mol%, preferably more than 0 mol% and 33 It is less than mol%, more preferably more than 0 mol% and less than 9 mol%, and particularly preferably more than 0 mol% and less than 3 mol%.
- the ratio of the repeating unit derived from the repeating unit (A), the repeating unit (B), or another monomer in the copolymer can be arbitrarily adjusted by changing the ratio of the monomer used in the polymerization. More specifically, the monomer a for constituting the repeating unit (A) may be added at a ratio of 1 to 7 mol% with respect to the total number of moles of all monomers used in the polymerization. Further, at this time, it is preferable to add the monomer b for constituting the repeating unit (B) at a ratio of 99 to 93 mol% with respect to the total number of moles of all monomers used.
- the charging ratio of the monomer used for the copolymerization Is the content ratio of each repeating unit in the copolymer obtained.
- the method for producing the copolymer contained in the antithrombotic material according to the present invention is not particularly limited.
- known polymerization methods such as radical polymerization, anionic polymerization, and cationic polymerization can be employed, and radical polymerization that is easy to produce is preferably used.
- plasma polymerization using radiation or ultraviolet rays may be employed, and a coat layer containing the copolymer may be formed on the substrate surface.
- the polymerization method of the monomer is usually one or two of monomers a corresponding to the above repeating unit (A) (for example, N-methacryloyloxyethyl-N, N-dimethylammonium- ⁇ -N-methylcarboxybetaine (CBA)).
- A for example, N-methacryloyloxyethyl-N, N-dimethylammonium- ⁇ -N-methylcarboxybetaine (CBA)
- CBA N-methacryloyloxyethyl-N, N-dimethylammonium- ⁇ -N-methylcarboxybetaine
- B for example, methoxyethyl acrylate (MEA)
- MEA methoxyethyl acrylate
- the polymerization temperature is preferably 30 ° C. to 100 ° C. from the viewpoint of controlling the molecular weight.
- the polymerization reaction is usually performed for 30 minutes to 24 hours.
- the polymerization solvent is preferably an aqueous solvent such as water; alcohols such as methanol, ethanol, propanol and n-butanol; polyhydric alcohols such as ethylene glycol, diethylene glycol, propylene glycol and dipropylene glycol; Methanol, ethanol or propanol is preferred. These may be used alone or in combination of two or more.
- the monomer concentration (solid content concentration) in the polymerization solvent is usually 10 to 90% by weight, preferably 15 to 80% by weight, based on the entire reaction solution.
- the monomer concentration with respect to the polymerization solvent is the monomer a, the monomer b, and other monomers copolymerizable with these (hereinafter referred to as “monomer a, monomer b, and optional copolymerized with these”). “Other possible monomers” are also referred to as “polymerization monomers”)).
- the polymerization solvent to which the polymerization monomer has been added may be subjected to a deaeration treatment before the addition of the polymerization initiator.
- a polymerization solvent added with a polymerization monomer may be bubbled with an inert gas such as nitrogen gas or argon gas for about 0.5 to 5 hours.
- the polymerization solvent to which the polymerization monomer is added may be heated to about 30 ° C. to 100 ° C.
- polymerization initiators can be used, and are not particularly limited.
- KPS potassium persulfate
- sodium persulfate sodium persulfate
- ammonium persulfate etc.
- Redox polymerization initiators in which a reducing agent such as sodium sulfite, sodium hydrogen sulfite, or ascorbic acid is combined with an oxidizing agent such as peroxide such as persulfate, hydrogen peroxide, t-butyl peroxide, methyl ethyl ketone peroxide, etc. Can be used.
- a reducing agent such as sodium sulfite, sodium hydrogen sulfite, or ascorbic acid
- an oxidizing agent such as peroxide such as persulfate, hydrogen peroxide, t-butyl peroxide, methyl ethyl ketone peroxide, etc.
- the blending amount of the polymerization initiator is, for example, 0.0001 to 1 mol with respect to all monomers (1 mol) used for the production of the copolymer.
- a chain transfer agent e.g., a polymerization rate adjusting agent, a surfactant, and other additives may be appropriately used during the polymerization.
- the atmosphere in which the polymerization reaction is performed is not particularly limited, and may be performed in an air atmosphere or an inert gas atmosphere such as nitrogen gas or argon gas. Further, during the polymerization reaction, the reaction solution may be stirred.
- the copolymer after polymerization can be purified by a general purification method such as a reprecipitation method, a dialysis method, an ultrafiltration method, or an extraction method.
- the purified copolymer can be dried by any method such as freeze-drying, reduced-pressure drying, spray drying, or heat drying. However, from the viewpoint of little influence on the physical properties of the polymer, freeze-drying or reduced pressure Drying is preferred.
- the antithrombogenic material according to the present invention may contain other components other than the copolymer.
- the other components include unreacted monomers that have not reacted in the polymerization, and various additives such as a crosslinking agent, a thickener, a preservative, and a pH adjuster.
- the unreacted polymerization monomer contained in the obtained copolymer is 0.01% by weight or less based on the entire copolymer.
- the content of the residual monomer can be measured by a method known to those skilled in the art, such as high performance liquid chromatography.
- the antithrombotic material in the present invention may be used in the form of the obtained copolymer, or may be processed into a gel form, a solution form, or the like.
- it can also be used as an antithrombogenic material in the form of a coating agent in which a copolymer is dissolved in a solvent.
- the solvent used is not particularly limited as long as it can dissolve the copolymer.
- alcohol solvents such as methanol, ethanol, isopropanol, butanol, water, chloroform, tetrahydrofuran, acetone,
- Non-proton donating organic solvents such as dioxane and benzene can be exemplified.
- the above solvents may be used alone or in combination of two or more.
- a water-alcohol solvent is preferable, and a water-methanol mixed solvent is particularly preferable.
- the amount of the copolymer contained in the coating agent can be arbitrarily set, and can be used as a solution in which the copolymer is dissolved up to the saturation amount. For example, 0.1 to 50% by weight based on the entire coating agent It is.
- the coating agent may be composed of the copolymer and the solvent, but may optionally contain other components such as a crosslinking agent, a thickener, a preservative, and a pH adjuster.
- a cross-linking agent By including a cross-linking agent, the copolymer can be more firmly fixed to the substrate surface.
- the repeating unit (A) contained in the antithrombogenic material according to the present invention easily reacts with the crosslinking agent, the antithrombogenic material can be more firmly immobilized on the substrate surface.
- the medical device of the present invention is formed by coating the surface of a base material with the above antithrombotic material.
- the material of the base material that can be used is not particularly limited.
- polyolefins such as polyethylene, polypropylene, and ethylene- ⁇ -olefin copolymers, and modified polyolefins; polyamides; polyimides; polyurethanes; polyethylene terephthalate (PET)
- PET polybutylene terephthalate
- PBT polycyclohexane terephthalate, polyethylene-2,6-naphthalate
- polyvinyl chloride polyvinylidene chloride (PVDC); polycarbonate; polytetrafluoroethylene (PTFE), ethylene-tetrafluoroethylene
- PTFE polytetrafluoroethylene
- examples thereof include various polymer materials such as a fluororesin such as a polymer (ETFE), metals such as SUS, ceramics, carbon, and composite materials thereof.
- the shape of the base material is appropriately selected depending on the use of the medical device, and can be, for example, a tube shape, a sheet shape, a rod shape, or the like.
- the form of the substrate is not limited to a molded body using the above-mentioned material alone, and a blend molded product, an alloyed molded product, a multilayered molded product, and the like can also be used.
- the substrate may be a single layer or may be laminated. At this time, when the base material is laminated, the base material of each layer may be the same or different. However, when it is desired to firmly fix the copolymer by swelling the substrate with a solvent, at least the material to be present on the surface of the substrate can be swollen well by the solvent of the coating agent of the antithrombotic material. preferable.
- the “base material surface” is a base material surface for a body fluid such as a biological tissue or blood.
- a coat layer having the copolymer is formed on the surface of the base material, the antithrombogenicity of the base material surface is improved.
- the substrate may be surface-treated before forming the coat layer on the substrate surface.
- the surface treatment method of the substrate include a method of irradiating active energy rays (electron beam, ultraviolet ray, X-ray, etc.), a method using plasma discharge such as arc discharge, corona discharge, glow discharge, etc., and a high electric field. Examples thereof include a method of applying, a method of applying ultrasonic vibration via a polar liquid (water or the like), a method of treating with ozone gas, and the like.
- the coating layer is formed by coating the antithrombotic material on the surface of the base material.
- Formation of the coating layer on the surface of the substrate is performed by coating the substrate surface by applying a coating solution containing the antithrombotic material (for example, the coating agent described above) or by polymerization for obtaining a copolymer.
- Plasma polymerization may be performed by applying a polymerization solvent containing a monomer to the substrate surface.
- “Coating” is not only a form in which the entire surface of the substrate is completely covered with the coat layer, but also a form in which a part of the surface of the substrate is covered with the coat layer, that is, the surface of the substrate. A form in which a coat layer is attached to a part of the film is also included.
- the coating layer is formed by coating the surface of the substrate with a coating solution containing an antithrombotic material
- the above-described method for preparing the coding agent is appropriately taken into consideration.
- a known method can be adopted as a method for applying a coating solution containing an antithrombotic material to the surface of the substrate, and is not particularly limited.
- the thickness of the coating solution may be appropriately adjusted depending on the use of the medical device, and is not particularly limited, but is, for example, 0.1 ⁇ m to 1 mm.
- a coating layer is formed on the surface of the substrate by drying the surface of the substrate to which the coating liquid containing the copolymer is applied.
- the drying process may be appropriately set in consideration of the glass transition temperature of the base material, etc., and is, for example, 15 to 50 ° C.
- the atmosphere in the drying step is not particularly limited, and can also be performed in the atmosphere under an inert gas atmosphere such as nitrogen gas or argon gas.
- Examples of the medical device according to the present invention include an implantable artificial organ and a therapeutic instrument, an extracorporeal circulation type artificial organ, a catheter, a guide wire, and the like.
- an artificial blood vessel, an artificial trachea, a stent, or an implantable medical device such as an artificial skin or an artificial pericardium, or an artificial heart system, an artificial lung system, an artificial heart lung or the like inserted into or replaced into a blood vessel or a lumen.
- an artificial lung system or the like is used continuously for a long time, and has a plurality of step portions in a tube connection portion or the like. Therefore, it is suitably used as an oxygenator system or an oxygenator system that contacts a large amount of blood.
- Example 1 Copolymer of CBA and MEA (Repeating unit (A): 1.78 mol%)] Methoxyethyl acrylate (MEA) 5 g (38.4 mmol) and N-methacryloyloxyethyl-N, N-dimethylammonium- ⁇ -N-methylcarboxybetaine (CBA, compound of the following chemical formula (i)) 0.15 g (0 .70 mmol) was dissolved in 25.5 g of methanol, placed in a four-necked flask, and N 2 bubbling was performed at 50 ° C. for 1 hour.
- MEA Methoxyethyl acrylate
- CBA N-methacryloyloxyethyl-N, N-dimethylammonium- ⁇ -N-methylcarboxybetaine
- Example 2 Copolymer of CBA and MEA (repeating unit (A): 3.50 mol%)]
- a polymer (2) was obtained in the same manner as in Example 1 except that the amount of CBA used was changed to 0.3 g (1.39 mmol) during preparation of the copolymer in Example 1. .
- the content ratio of the repeating unit (A) in the polymer (2) was measured by 1 H-NMR, it was the same ratio as the value calculated from the charged amount. Further, the content ratio of the repeating unit (B) was the same ratio (96.50 mol%) as the value calculated from the charged amount.
- Example 3 Copolymer of CBA and MEA (Repeating unit (A): 5.16 mol%)]
- a polymer (3) was obtained in the same manner as in Example 1 except that the amount of CBA used was changed to 0.45 g (2.09 mmol) during preparation of the copolymer in Example 1. .
- the content ratio of the repeating unit (A) in the polymer (3) was measured by 1 H-NMR, it was the same ratio as the value calculated from the charged amount. Further, the content ratio of the repeating unit (B) was the same ratio (94.84 mol%) as the value calculated from the charged amount.
- Comparative Example 1 Copolymer of CBA and MEA (Repeating unit (A): 8.82 mol%)]
- a comparative polymer (1) was obtained in the same manner as in Example 1 except that the amount of CBA used was changed to 0.8 g (3.72 mmol) during preparation of the copolymer in Example 1. It was.
- the content ratio of the repeating unit (A) in the comparative polymer (1) was measured by 1 H-NMR, it was the same ratio as the value calculated from the charged amount. Further, the content ratio of the repeating unit (B) was the same ratio (91.18 mol%) as the value calculated from the charged amount.
- Comparative Example 2 Copolymer of CBA and MEA (Repeating unit (A): 0.84 mol%)]
- a comparative polymer (2) was obtained in the same manner as in Example 1 except that the amount of CBA used was changed to 0.07 g (0.33 mmol) during preparation of the copolymer in Example 1. It was.
- the content ratio of the repeating unit (A) in the comparative polymer (2) was measured by 1 H-NMR, it was the same ratio as the value calculated from the charged amount. Further, the content ratio of the repeating unit (B) was the same ratio (99.16 mol%) as the value calculated from the charged amount.
- Example 5 MEA (homo) polymer (repeating unit (A): 0 mol%)
- a comparative polymer (5) was obtained in the same manner as in Example 1 except that only 5 g (38.4 mmol) of MEA was used at the time of preparing the copolymer in Example 1. That is, a homopolymer of MEA was obtained as a comparative polymer (5).
- the weight average molecular weight of the comparative polymer (5) was 130,000. The weight average molecular weight was measured by GPC as described above.
- the polymers (1) to (3) and comparative polymers (1) to (5) obtained in the above examples or comparative examples were purified by a reprecipitation method in diethyl ether. Thereafter, these copolymers or polymers were dried by vacuum drying and subjected to the following tests.
- the base material can be appropriately coated with the antithrombotic material, and the antithrombogenic material is based on It turns out that it can prevent more effectively that a coating layer peels from a material and mixes into blood.
- repeating unit (A) when the repeating unit (A) is 6 mol% or less in all the structural units of the copolymer, dissolution in physiological saline can be particularly suppressed. Therefore, if the repeating unit (A) is 6 mol% or less in all the structural units of the copolymer, it is more effective that the antithrombotic material is peeled off from the base material and mixed into the blood. It is suggested that it can be prevented.
- a stepped tube was prepared by inserting a 1 cm end of a soft vinyl chloride tube (tube 2) having a total length of 5 cm, an inner diameter of 6 mm and an outer diameter of 9 mm into both ends of a soft vinyl chloride tube (tube 1) having a total length of 30 cm and an inner diameter of 8 mm. .
- FIG. 1 shows the manufactured step tube.
- a circled portion indicates a joint portion between the tube 1 and the tube 2.
- FIG. 2 is an enlarged view schematically showing a joint portion between the tube 1 and the tube 2 in FIG. Since the inner diameter of the tube 2 is thinner than the inner diameter of the tube 1, a step surface 3 is formed. When blood is passed through the step tube, a thrombus is very easily formed on the step surface 3.
- the prepared step tube was used as a substrate, the above coating agent was passed through the step tube, and the coating agent was applied to the substrate surface. Thereafter, the step tube was dried at room temperature (25 ° C.), and a coat layer containing an antithrombotic material was formed on the substrate surface (step tube lumen surface).
- the (co) polymers obtained in the above Examples and Comparative Examples were each dissolved in methanol to prepare a 0.5 wt% solution, and dip coated to form a coat layer.
- Anti-thrombogenicity test In order to evaluate the antithrombogenicity of the antithrombotic material under harsh conditions in which a thrombus is easily formed, the following test system was constructed using the above-described stepped tube having a coating layer formed thereon.
- the lumen of the stepped tube on which the coat layer was formed was filled with 6 ml of a solution (diluted blood) obtained by diluting human fresh blood twice with physiological saline. Both ends of the step tube were connected with connectors, fixed to a cylindrical rotating device, and rotated at 40 rpm for 2 hours. Thereafter, the circulating blood was removed from the stepped tube, and the adhesion state of the thrombus (shown by reference numeral “4” in FIG. 4) to the joint portion (stepped surface) between the tube 1 and the tube 2 was visually observed.
- the fresh blood refers to blood collected from a healthy donor by whole blood transfusion within 30 minutes. In addition, no anticoagulant is added to fresh blood.
- FIG. 3 shows the joint produced immediately after the antithrombogenicity test for the stepped tube to which the coating layer containing the copolymer produced in Example 1 and FIG. 4 shows the polymer produced in Comparative Example 3 respectively. It is an enlarged photo. Thrombus formation was not observed in the stepped tube to which the copolymer according to the present invention was applied (FIG. 3). On the other hand, in the stepped tube to which the polymer of Comparative Example 3 was applied, thrombus 4 was observed at the joint (FIG. 4).
- the medical device according to the present invention exhibits high antithrombogenicity.
- the repeating unit (A) is 1 mol% or more in all the structural units of the copolymer, high antithrombogenicity can be obtained even under severe use conditions. Furthermore, in the antithrombogenicity test, according to visual evaluation, it was found that particularly excellent antithrombogenicity was obtained when the repeating unit (A) was 2 to 6 mol%.
- FIG. 4 of Japanese Patent Application Laid-Open No. 2009-219936 An artificial lung having the structure disclosed in 1); as a base material constituting a blood circulation path, polypropylene, polyurethane, polycarbonate, and SUS are included) from the blood import side, and after leaving for 120 seconds, they are removed. The mixture was blown and dried at room temperature (25 ° C.) for 240 minutes.
- the blood circulation module was incorporated into an extracorporeal circuit by connecting to a blood reservoir using a connection tube (made of soft vinyl chloride, total length: about 100 cm ⁇ inner diameter: 8 mm). Subsequently, 200 ml of lactated Ringer's solution was filled into the extracorporeal circuit, and then 200 ml of heparinized human fresh blood was added. The heparin concentration in the circulating blood was 0.5 unit / ml. Circulation was performed at room temperature (25 ° C.) at 500 ml / min.
- TAT thrombin antithrombin complex
- the TAT concentration was lower than that of the blood circulation module coated with the comparative polymer (5) of Comparative Example 5. That is, it was confirmed that the medical device according to the present invention has an excellent antithrombotic property with low activation of the blood coagulation system.
- the blood circulation route was washed with phosphate buffered saline (PBS), and the site where blood was likely to stagnate was observed.
- PBS phosphate buffered saline
- adhesion of thrombus (indicated by reference numeral “4” in FIG. 5) was hardly observed.
- adhesion of thrombus indicated by reference numeral “4” in FIG. 6) was confirmed. It was confirmed that the polymer (1) of Example 1 had excellent antithrombotic properties even in the simulated product.
- the medical device according to the present invention is used under severe conditions in which a thrombus such as a step having a stepped portion on a surface in contact with blood is easily formed, such as a medical device having a throttle portion such as a joint portion of a tube. Even in the case of the anti-thrombotic properties,
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Surgery (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Materials Engineering (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Materials For Medical Uses (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
Abstract
Description
前記抗血栓性材料は、
下記式(1):
で示される繰り返し単位(A)と、
下記式(2):
で示される繰り返し単位(B)と、を有する共重合体を含み、
前記繰り返し単位(A)が、前記共重合体の全構成単位中、1~7モル%含まれる、医療用具;
2.前記式(2)中、R21は、水素原子またはメチル基であり、R22は、炭素原子数1~3のアルキレン基であり、R23は、炭素原子数1または2のアルキル基である、上記1.に記載の医療用具;
3.前記式(1)中、R11はメチル基であり、Zは酸素原子であり、R12は炭素原子数1~3のアルキレン基であり、R13およびR14はそれぞれ独立して炭素原子数1または2のアルキル基である、上記1.または2.に記載の医療用具;
4.前記共重合体は、前記繰り返し単位(A)を1~7モル%、前記繰り返し単位(B)を99~93モル%(前記繰り返し単位(A)および前記繰り返し単位(B)の合計量は100モル%である)から構成される、上記1.~3.のいずれかに記載の医療用具。
下記式(1):
で示される繰り返し単位(A)と、
下記式(2):
で示される繰り返し単位(B)と、を有する共重合体を含み、
前記繰り返し単位(A)が、全構成単位中、1~7モル%含まれる、医療用具を提供する。
本発明に係る医療用具において、コート層は、基材表面の少なくとも一部を被覆する層であり、医療用具に抗血栓性を付与するために設けられる。
本発明に係る抗血栓性材料に含まれる共重合体は、上記繰り返し単位(A)および(B)を含み、かつ、全構成単位中、繰り返し単位(A)の含有比率が特定の範囲内である共重合体である。したがって、上記組成を有していれば、共重合体の末端は特に制限されず、使用される原料の種類によって適宜規定されるが、通常、水素原子である。共重合体の構造も特に制限されず、ランダム共重合体、交互共重合体、周期的共重合体、ブロック共重合体のいずれであってもよい。
本発明において、抗血栓性材料に含まれる共重合体は、上記式(1)で示される繰り返し単位(A)を必須に含む。
本発明において、抗血栓性材料に含まれる共重合体は、上記式(2)で示される繰り返し単位(B)を必須に含む。
本発明において、共重合体は、共重合体の全構成単位(100モル%)中、繰り返し単位(A)を、1~7モル%含む。繰り返し単位(A)は、親水性が高いため、共重合体に多く含まれる場合、当該共重合体は良好な抗血栓性を示す。一方で、繰り返し単位(A)が多すぎると、共重合体の水溶性が高くなり、医療用具に抗血栓性材料を適用した際、抗血栓性材料が剥離してしまう虞がある。
上記のように、本発明に係る抗血栓性材料に含まれる共重合体は、繰り返し単位(A)および(B)のみからなると好ましいが、その他の繰り返し単位を含んでいてもよい。すなわち、本発明の他の実施形態において、抗血栓性材料に含まれる共重合体は、モノマーa、モノマーb、および、これらと共重合可能な他のモノマー(以下、単に「他のモノマー」とも称する。)に由来する構成単位(繰り返し単位)を含んでいてもよい。
共重合体における繰り返し単位(A)、繰り返し単位(B)、または他のモノマーに由来する繰り返し単位の割合は、重合の際に用いるモノマーの割合を変更することで、任意に調整できる。より詳細には、重合の際、用いる全モノマーの総モル数に対して、繰り返し単位(A)を構成するためのモノマーaを、1~7モル%の割合で添加すればよい。さらにこのとき、繰り返し単位(B)を構成するためのモノマーbを、用いる全モノマーの総モル数に対して99~93モル%の割合で添加すると好ましい。基本的には、モノマーa、モノマーb、および任意で添加される他のモノマーの共重合により得られた共重合体について、分子量分画等を行わない場合、共重合に用いたモノマーの仕込み比率が、得られる共重合体中の各繰り返し単位の含有比率となる。
本発明に係る抗血栓性材料は、上記共重合体以外の、他の成分を含んでいてもよい。当該他の成分としては、例えば、重合において反応しなかった未反応のモノマーや、架橋剤、増粘剤、防腐剤、pH調整剤等の各種添加剤が挙げられる。
本発明の医療用具は、上記の抗血栓性材料によって基材表面が被覆されてなる。このとき、使用可能な基材の材質としては、特に制限されず、例えば、ポリエチレン、ポリプロピレン、エチレン-α-オレフィン共重合体等のポリオレフィンや変性ポリオレフィン;ポリアミド;ポリイミド;ポリウレタン;ポリエチレンテレフタレート(PET)、ポリブチレンテレフタレート(PBT)、ポリシクロヘキサンテレフタレート、ポリエチレン-2,6-ナフタレート等のポリエステル;ポリ塩化ビニル;ポリ塩化ビニリデン(PVDC);ポリカーボネート;ポリテトラフルオロエチレン(PTFE)、エチレン-テトラフルオロエチレン共重合体(ETFE)等のフッ素樹脂等の各種高分子材料、SUS等の金属、セラミック、カーボン、およびこれらの複合材料等が例示できる。
本発明に係る医療用具においては、上記抗血栓性材料を基材表面に被覆することにより、コート層が形成される。
本発明に係る医療用具としては、例えば、体内埋入型の人工器官や治療器具、体外循環型の人工臓器類、カテーテル、ガイドワイヤー等を例示できる。具体的には、血管や管腔内へ挿入あるいは置換される人工血管、人工気管、ステントや、人工皮膚、人工心膜等の埋入型医療器具や、人工心臓システム、人工肺システム、人工心肺システム、人工腎臓システム、人工肝臓システム、免疫調節システム等の人工臓器システムや、留置針、IVHカテーテル、薬液投与用カテーテル、サーモダイリューションカテーテル、血管造影用カテーテル、血管拡張用カテーテルおよびダイレーターあるいはイントロデューサー等の血管内に挿入ないし留置されるカテーテルや、あるいは、これらのカテーテル用のガイドワイヤー、スタイレット等や、胃管カテーテル、栄養カテーテル、経管栄養用(ED)チューブ、尿道カテーテル、導尿カテーテル、バルーンカテーテル、気管内吸引カテーテルをはじめとする各種の吸引カテーテルや排液カテーテル等の血管以外の生体組織に挿入ないし留置されるカテーテル類が例示できる。特に、人工肺システム等は、長時間連続して使用され、かつ、チューブの連結部等において複数の段差部を有している。そのため、大量の血液と接する人工肺システム、または人工心肺システムとして好適に使用される。
アクリル酸メトキシエチル(MEA)5g(38.4mmol)とN-メタクリロイルオキシエチル-N,N-ジメチルアンモニウム-α-N-メチルカルボキシベタイン(CBA、下記化学式(i)の化合物)0.15g(0.70mmol)とをメタノール25.5gに溶解し、四口フラスコに入れ、50℃でN2バブリングを1時間行った。
実施例1における共重合体の調製時、用いたCBAの量を変更して0.3g(1.39mmol)としたこと以外は、上記実施例1と同様にして重合体(2)を得た。当該重合体(2)における繰り返し単位(A)の含有比率を1H-NMRにより測定したところ、上記の仕込み量から計算される値と同様の比率であった。また、繰り返し単位(B)の含有比率も仕込み量から計算される値と同様の比率(96.50モル%)であった。
実施例1における共重合体の調製時、用いたCBAの量を変更して0.45g(2.09mmol)としたこと以外は、上記実施例1と同様にして重合体(3)を得た。当該重合体(3)における繰り返し単位(A)の含有比率を1H-NMRにより測定したところ、上記の仕込み量から計算される値と同様の比率であった。また、繰り返し単位(B)の含有比率も仕込み量から計算される値と同様の比率(94.84モル%)であった。
実施例1における共重合体の調製時、用いたCBAの量を変更して0.8g(3.72mmol)としたこと以外は、上記実施例1と同様にして比較重合体(1)を得た。当該比較重合体(1)における繰り返し単位(A)の含有比率を1H-NMRにより測定したところ、上記の仕込み量から計算される値と同様の比率であった。また、繰り返し単位(B)の含有比率も仕込み量から計算される値と同様の比率(91.18モル%)であった。
実施例1における共重合体の調製時、用いたCBAの量を変更して0.07g(0.33mmol)としたこと以外は、上記実施例1と同様にして比較重合体(2)を得た。当該比較重合体(2)における繰り返し単位(A)の含有比率を1H-NMRにより測定したところ、上記の仕込み量から計算される値と同様の比率であった。また、繰り返し単位(B)の含有比率も仕込み量から計算される値と同様の比率(99.16モル%)であった。
実施例1における共重合体の調製時、用いたMEAの代わりにヘキシルメタクリレート(HMA)4g(23.49mmol)を用い、CBAの量を変更して2.4g(11.15mmol)としたこと以外は、上記実施例1と同様にして比較重合体(3)を得た。当該比較重合体(3)における繰り返し単位(A)の含有比率を1H-NMRにより測定したところ、上記の仕込み量から計算される値と同様の比率であった。また、HMAに由来する繰り返し単位の含有比率も仕込み量から計算される値と同様の比率(67.82モル%)であった。
共重合体の調製時、用いたMEAの代わりにブチルメタクリレート(BMA)5.5g(38.68mmol)を用い、CBAの量を変更して4.5g(20.90mmol)とし、メタノール50gに溶解したこと以外は、上記実施例1と同様にして比較重合体(4)を得た。当該重合体(4)における繰り返し単位(A)の含有比率を1H-NMRにより測定したところ、上記の仕込み量から計算される値と同様の比率であった。また、BMAに由来する繰り返し単位の含有比率も仕込み量から計算される値と同様の比率(64.92モル%)であった。
実施例1における共重合体の調製時、MEA 5g(38.4mmol)のみを使用したこと以外は、上記実施例1と同様にして比較重合体(5)を得た。すなわち、MEAの単独重合体を比較重合体(5)として得た。また、当該比較重合体(5)の重量平均分子量は130000であった。なお、重量平均分子量の測定は、上記のとおり、GPCにより測定した。
実施例または比較例で得られた、重合体(1)~(3)および比較重合体(1)をそれぞれ0.1gずつ量り採り、それぞれ別のガラス製試験管に入れた。
(コーティング剤の調製)
実施例または比較例で得られた、上記重合体(1)~(3)および比較重合体(2)~(5)のそれぞれについて、0.5重量%のメタノール溶液を調製し、コーティング剤とした。
全長30cm×内径8mmの軟質塩化ビニルチューブ(チューブ1)の両端にそれぞれ、全長5cm×内径6mm×外径9mmの軟質塩化ビニルチューブ(チューブ2)の端部1cmを挿入し、段差チューブを作製した。
血栓が形成されやすい過酷な条件における抗血栓性材料の抗血栓性を評価するため、コート層を形成した上記段差チューブを用いて、以下のような試験系を構築した。
上記実施例1で得られた重合体(1)および比較例5で得られた比較重合体(5)をコートした基材について、下記方法に従って、抗血栓性を評価した。
重合体(1)および比較重合体(5)をそれぞれ、0.2重量%の濃度で、水-アルコール(メタノール)混合溶液に溶解させ、コーティング剤とした。
上記コーティング剤を、模擬製品形態(血液循環モジュール:特開平11-114056号公報に開示された実施例1に係る血液外部灌流型中空糸膜人工肺を、特開2009-219936号公報の図4に開示された構造を有する人工肺としたもの;血液循環経路を構成する基材として、ポリプロピレン、ポリウレタン、ポリカーボネート、SUSを含む)に血液インポート側から充填し、120秒間静置した後に除去し、室温(25℃)で240分間、送風乾燥した。
上記血液循環モジュールを接続チューブ(軟質塩化ビニル製、全長約100cm×内径8mm)を用いて貯血槽と接続することによって体外循環回路中に組み込んだ。続いて、乳酸リンゲル液200mlを上記体外循環回路に充填し、その後、ヘパリン添加ヒト新鮮血200mlを添加した。循環血液中のへパリン濃度は、0.5単位/mlとした。室温(25℃)、500ml/minで循環させた。循環開始から120分後に、それぞれの血液循環回路から血液をサンプリングし、血液凝固系の活性化指標であるトロンビンアンチトロンビン複合体(TAT)の濃度を測定した。TAT濃度は、EIA法による測定キットを用いた。高いTAT濃度は、凝固活性化状態にあることを示し、血栓が生じやすいといえる。
2 チューブ2、
3 段差面、
4 血栓。
Claims (4)
- 基材と、前記基材表面を被覆する抗血栓性材料を含むコート層と、を有する医療用具であって、
前記抗血栓性材料は、
下記式(1):
で示される繰り返し単位(A)と、
下記式(2):
で示される繰り返し単位(B)と、を有する共重合体を含み、
前記繰り返し単位(A)が、前記共重合体の全構成単位中、1~7モル%含まれる、医療用具。 - 前記式(2)中、R21は、水素原子またはメチル基であり、R22は、炭素原子数1~3のアルキレン基であり、R23は、炭素原子数1または2のアルキル基である、請求項1に記載の医療用具。
- 前記式(1)中、R11はメチル基であり、Zは酸素原子であり、R12は炭素原子数1~3のアルキレン基であり、R13およびR14はそれぞれ独立して炭素原子数1または2のアルキル基である、請求項1または2に記載の医療用具。
- 前記共重合体は、前記繰り返し単位(A)を1~7モル%、前記繰り返し単位(B)を99~93モル%(前記繰り返し単位(A)および前記繰り返し単位(B)の合計量は100モル%である)から構成される、請求項1~3のいずれか1項に記載の医療用具。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14875327.0A EP3088014B1 (en) | 2013-12-27 | 2014-12-19 | Medical device |
JP2015554840A JP6373872B2 (ja) | 2013-12-27 | 2014-12-19 | 医療用具 |
US15/193,888 US10022478B2 (en) | 2013-12-27 | 2016-06-27 | Medical device |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013270963 | 2013-12-27 | ||
JP2013-270963 | 2013-12-27 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/193,888 Continuation US10022478B2 (en) | 2013-12-27 | 2016-06-27 | Medical device |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015098763A1 true WO2015098763A1 (ja) | 2015-07-02 |
Family
ID=53478620
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2014/083755 WO2015098763A1 (ja) | 2013-12-27 | 2014-12-19 | 医療用具 |
Country Status (4)
Country | Link |
---|---|
US (1) | US10022478B2 (ja) |
EP (1) | EP3088014B1 (ja) |
JP (1) | JP6373872B2 (ja) |
WO (1) | WO2015098763A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020009008A1 (ja) | 2018-07-02 | 2020-01-09 | 旭化成メディカル株式会社 | 血液処理用ビーズ |
WO2020203927A1 (ja) | 2019-03-29 | 2020-10-08 | 旭化成メディカル株式会社 | 血液浄化器 |
WO2020203923A1 (ja) | 2019-03-29 | 2020-10-08 | 旭化成メディカル株式会社 | 血液浄化器 |
EP3824921A1 (en) | 2018-07-02 | 2021-05-26 | Asahi Kasei Medical Co., Ltd. | Beads for blood processing |
US11427503B2 (en) | 2017-06-23 | 2022-08-30 | AGC Inc. | Chemically-strengthened glass |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140083628A1 (en) | 2012-09-27 | 2014-03-27 | Velico Medical, Inc. | Spray drier assembly for automated spray drying |
US9561184B2 (en) | 2014-09-19 | 2017-02-07 | Velico Medical, Inc. | Methods and systems for multi-stage drying of plasma |
US11998861B2 (en) | 2022-09-15 | 2024-06-04 | Velico Medical, Inc. | Usability of a disposable for a spray drying plasma system |
US11841189B1 (en) | 2022-09-15 | 2023-12-12 | Velico Medical, Inc. | Disposable for a spray drying system |
US11975274B2 (en) | 2022-09-15 | 2024-05-07 | Velico Medical, Inc. | Blood plasma product |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04152952A (ja) | 1990-10-18 | 1992-05-26 | Terumo Corp | 生体適合性医用材料 |
US5756785A (en) * | 1997-03-21 | 1998-05-26 | Lambent Technologies, Inc. | Guerbet betaines |
JPH11114056A (ja) | 1997-10-09 | 1999-04-27 | Terumo Corp | 中空糸膜外部血液灌流型人工肺 |
JP2003111836A (ja) * | 2001-06-28 | 2003-04-15 | Terumo Corp | 人工心肺回路システム |
WO2005113620A1 (ja) | 2004-05-20 | 2005-12-01 | Osaka Organic Chemical Ind., Ltd. | 生体適合性材料 |
JP2007130194A (ja) * | 2005-11-10 | 2007-05-31 | Osaka Organic Chem Ind Ltd | 医療用材料 |
JP2008274151A (ja) * | 2007-05-01 | 2008-11-13 | Teika Seiyaku Kk | 創傷被覆組成物および創傷被覆材 |
JP2009219936A (ja) | 2009-07-10 | 2009-10-01 | Terumo Corp | 人工肺 |
JP2010057745A (ja) * | 2008-09-04 | 2010-03-18 | Osaka Organic Chem Ind Ltd | 医療用材料 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6994824B2 (en) * | 2001-06-28 | 2006-02-07 | Terumo Kabushiki Kaisha | Artificial cardiopulmonary circuit system |
WO2008032758A1 (en) * | 2006-09-15 | 2008-03-20 | Toray Industries, Inc. | Substrate and method for production thereof |
WO2010065958A1 (en) * | 2008-12-05 | 2010-06-10 | Semprus Biosciences Corp. | Layered non-fouling, antimicrobial, antithrombogenic coatings |
-
2014
- 2014-12-19 WO PCT/JP2014/083755 patent/WO2015098763A1/ja active Application Filing
- 2014-12-19 JP JP2015554840A patent/JP6373872B2/ja active Active
- 2014-12-19 EP EP14875327.0A patent/EP3088014B1/en active Active
-
2016
- 2016-06-27 US US15/193,888 patent/US10022478B2/en active Active
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04152952A (ja) | 1990-10-18 | 1992-05-26 | Terumo Corp | 生体適合性医用材料 |
US5756785A (en) * | 1997-03-21 | 1998-05-26 | Lambent Technologies, Inc. | Guerbet betaines |
JPH11114056A (ja) | 1997-10-09 | 1999-04-27 | Terumo Corp | 中空糸膜外部血液灌流型人工肺 |
JP2003111836A (ja) * | 2001-06-28 | 2003-04-15 | Terumo Corp | 人工心肺回路システム |
WO2005113620A1 (ja) | 2004-05-20 | 2005-12-01 | Osaka Organic Chemical Ind., Ltd. | 生体適合性材料 |
US20080262181A1 (en) | 2004-05-20 | 2008-10-23 | Oska Organic Cmeical Ind., Ltd. | Biocompatible Material |
JP2007130194A (ja) * | 2005-11-10 | 2007-05-31 | Osaka Organic Chem Ind Ltd | 医療用材料 |
JP2008274151A (ja) * | 2007-05-01 | 2008-11-13 | Teika Seiyaku Kk | 創傷被覆組成物および創傷被覆材 |
JP2010057745A (ja) * | 2008-09-04 | 2010-03-18 | Osaka Organic Chem Ind Ltd | 医療用材料 |
JP2009219936A (ja) | 2009-07-10 | 2009-10-01 | Terumo Corp | 人工肺 |
Non-Patent Citations (1)
Title |
---|
See also references of EP3088014A4 |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11427503B2 (en) | 2017-06-23 | 2022-08-30 | AGC Inc. | Chemically-strengthened glass |
WO2020009008A1 (ja) | 2018-07-02 | 2020-01-09 | 旭化成メディカル株式会社 | 血液処理用ビーズ |
EP3824921A1 (en) | 2018-07-02 | 2021-05-26 | Asahi Kasei Medical Co., Ltd. | Beads for blood processing |
WO2020203927A1 (ja) | 2019-03-29 | 2020-10-08 | 旭化成メディカル株式会社 | 血液浄化器 |
WO2020203923A1 (ja) | 2019-03-29 | 2020-10-08 | 旭化成メディカル株式会社 | 血液浄化器 |
Also Published As
Publication number | Publication date |
---|---|
EP3088014B1 (en) | 2018-06-20 |
US20160303296A1 (en) | 2016-10-20 |
JP6373872B2 (ja) | 2018-08-15 |
JPWO2015098763A1 (ja) | 2017-03-23 |
EP3088014A4 (en) | 2017-08-23 |
US10022478B2 (en) | 2018-07-17 |
EP3088014A1 (en) | 2016-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6373872B2 (ja) | 医療用具 | |
US20160375180A1 (en) | Method for producing medical device and medical device | |
JP6600560B2 (ja) | 抗血栓性コーティング材の製造方法 | |
JP5969484B2 (ja) | 抗血栓性材料および医療用具 | |
JP6397889B2 (ja) | 医療材料、および該医療材料を利用した医療用具 | |
JP7209643B2 (ja) | 医療用コーティング材料および該医療用コーティング材料を利用した医療用具 | |
WO2020004385A1 (ja) | 親水性共重合体および医療用具 | |
JP6456196B2 (ja) | 抗血栓性接着用組成物、ならびに該抗血栓性接着用組成物を利用した医療用具およびその製造方法 | |
JP2014147638A (ja) | 医療用具の製造方法 | |
WO2015098764A1 (ja) | 抗血栓性医療材料、および該医療材料を利用した医療用具 | |
JP6278731B2 (ja) | 抗血栓性医療材料、および該医療材料を利用した医療用具 | |
JP2014147639A (ja) | 医療用具 | |
JP3540457B2 (ja) | 抗血栓性を賦与した医療用基材 | |
WO2014123077A1 (ja) | 医療用コーティング材料および医療用具 | |
JP2018149270A (ja) | 抗血栓性コーティング材 | |
JP2015097550A (ja) | 血液適合性材料および医療用具 | |
JP6640584B2 (ja) | 医療用具およびその製造方法 | |
US20210115350A1 (en) | UV Cure Topcoatings For Medical Devices |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14875327 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2015554840 Country of ref document: JP Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2014875327 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014875327 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |